MARKET

ZTS

ZTS

Zoetis Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

158.63
-0.23
-0.14%
After Hours: 158.63 0 0.00% 16:35 05/19 EDT
OPEN
158.14
PREV CLOSE
158.86
HIGH
160.35
LOW
156.67
VOLUME
2.96M
TURNOVER
0
52 WEEK HIGH
249.27
52 WEEK LOW
156.67
MARKET CAP
74.66B
P/E (TTM)
36.40
1D
5D
1M
3M
1Y
5Y
Zoetis declares $0.325 dividend
Zoetis (NYSE:ZTS) declares $0.325/share quarterly dividend, in line with previous. Forward yield 0.82% Payable Sept. 1; for shareholders of record July 21; ex-div July 20. See ZTS Dividend Scorecard, Yield
Seekingalpha · 2h ago
--Zoetis Maintains Quarterly Dividend at $0.325 a Share, Payable Sep. 1 to Shareholders as of July 21
MT Newswires · 6h ago
Goldman Sachs Adjusts Price Target for Zoetis to $208 From $237, Maintains Buy Rating
MT Newswires · 13h ago
Research Alert: CFRA Keeps Hold Opinion On Shares Of Zoetis Inc.
MT Newswires · 05/06 14:08
Investing in Zoetis (NYSE:ZTS) five years ago would have delivered you a 204% gain
While Zoetis Inc. ( NYSE:ZTS ) shareholders are probably generally happy, the stock hasn't had particularly good run...
Simply Wall St. · 05/05 17:54
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.
Zacks · 05/05 15:07
Zoetis Delivers First-Quarter Beat, But Guidance Takes An Unexpected Hit
Zoetis beat first-quarter expectations Thursday and ZTS stock rose higher despite the company's unexpected guidance cut.
Investor's Business Daily · 05/05 12:50
Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:25
More
No Data
Learn about the latest financial forecast of ZTS. Analyze the recent business situations of Zoetis Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
50.00%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZTS stock price target is 241.18 with a high estimate of 275.00 and a low estimate of 205.00.
High275.00
Average241.18
Low205.00
Current 158.63
EPS
Actual
Estimate
0.330.660.991.32
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 2.01K
Institutional Holdings: 468.19M
% Owned: 99.48%
Shares Outstanding: 470.63M
TypeInstitutionsShares
Increased
596
13.74M
New
259
3.87M
Decreased
512
15.30M
Sold Out
63
963.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.15%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Michael Mccallister
Chief Executive Officer/Director
Kristin Peck
Chief Financial Officer/Executive Vice President
Wetteny Joseph
Chief Human Resource Officer/Executive Vice President
Roxanne Lagano
Executive Vice President/Chief Information Officer
Wafaa Mamilli
Executive Vice President/General Counsel/Secretary
Heidi Chen
Executive Vice President
Timothy Bettington
Executive Vice President
Glenn David
Executive Vice President
Jeannette Ferran Astorga
Executive Vice President
Abhay Nayak
Executive Vice President
Robert Polzer
Executive Vice President
Roman Trawicki
Independent Director
Paul Bisaro
Independent Director
Frank D'amelio
Independent Director
Sanjay Khosla
Independent Director
Antoinette Leatherberry
Independent Director
Gregory Norden
Independent Director
Louise Parent
Independent Director
Willie Reed
Independent Director
Linda Rhodes
Independent Director
Robert Scully
No Data
No Data
About ZTS
Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision livestock farming technology. The Company has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers.

Webull offers kinds of Zoetis Inc stock information, including NYSE:ZTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZTS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZTS stock methods without spending real money on the virtual paper trading platform.